A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Conditions: Leukemia; Lymphoma; Lymphoma, B-Cell Intervention: Biological: CAR T-Cell Infusion Sponsor: Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials